COMPACT 12 LEAD ECG DEVICE PUSHES EARLY HEALTH FORWARD IN THE UK & IRELAND
GE HEALTCARE'S MAC 400 HELPS CLINICIANS MAKE MORE INFORMED, FASTER DIAGNOSES
HATFIELD, HERTS, UK - 15TH OCTOBER 2007 GE Healthcare, a unit of General Electric Company (NYSE: GE), is making a big push for Early Health in UK & Ireland to ensure that more residents around the world have access to reliable diagnostics for better and earlier treatment.
The MAC 400 from GE's new compact line is a unique ECG, designed to help physicians in emerging markets, whether they work in a hospital setting or in a private practice, to better predict and diagnose patients at risk of heart disease. It is highly portable, easy-to-use and allows for various patients' configurations to assist the physician in making faster, more confident cardiac assessment and providing better patient care.
The same quality and clinical excellence of the Marquette 12SL algorithm that reside in GE Healthcare's premium ECG devices is made available in the compact MAC 400 to help every physician use GE technology and perform reliable ECG's on every patient. This is bringing to life GE Healthcare's vision of Early Health by introducing diagnostic technology to every corner of the world and making healthcare more accessible to larger sections of society.
Measuring the electrical activity of the heart through an ECG is the very first step in diagnosing heart disease. This is why it is essential to make this procedure available to every physician, every patient, everywhere including the emerging countries. The combination of GE's legacy in clinical excellence, its trusted ECG quality and our high standards in manufacturing processes, all contribute to making the new MAC 400 the appropriate ECG solution for a physician office, says Matthias Weber, Vice President of Diagnostic Cardiology.
Announcing GE Healthcare's big push for Early Health in India earlier this year, Joe Hogan, President and CEO GE Healthcare said, Today, 70 to 80% of the resources in healthcare are devoted to managing symptom-based, advanced disease. If we can move from a see and treat approach to healthcare to one where the focus is on predictive healthcare we can dramatically reduce the costs to patients of late-stage treatment. Shifting resources to develop technologies that allow healthcare providers to diagnose disease at the earliest possible stage, when there can be many treatment options, is better medicine. It also makes simple economic sense.
Since 1965, GE has been introducing technologic innovation, which has profoundly impacted clinical guidelines and ECG standards. Today, through its collaboration with world-leading cardiologists, GE continues to develop ECG products of the highest quality standards. GE is the only medical manufacturing company to have predictive algorithms that meet the AHA guidelines.
For more information about GE Healthcare, visit our website at www.gehealthcare.com or contact:
Chris Hughes-Jones UK Cardiology Product Manager GE Healthcare 71 Great North Road Hatfield Herts, UK AL9 5EN
Tel Office: 01707 263570